Mangoceuticals, Common Ownership

MGRX Stock

2.81 1.94 40.84%

The market capitalization of Mangoceuticals, Common Stock is USD23.6 Million. Mangoceuticals, Common Stock holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Some institutional investors establish a significant position in stocks such as Mangoceuticals, Common in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Mangoceuticals, Common, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Market Cap Enterprise Value

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mangoceuticals, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Mangoceuticals, Stock Ownership Analysis

About 36.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mangoceuticals, Common recorded a loss per share of 4.84. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 16th of October 2024. To find out more about Mangoceuticals, Common Stock contact Jacob Cohen at 214 242 9619 or learn more at https://www.mangoceuticals.com.

Besides selling stocks to institutional investors, Mangoceuticals, Common also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Mangoceuticals, Common's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Mangoceuticals, Common's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Mangoceuticals, Common Quarterly Liabilities And Stockholders Equity

15.37 Million

About 36.0% of Mangoceuticals, Common Stock are currently held by insiders. Unlike Mangoceuticals, Common's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Mangoceuticals, Common's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Mangoceuticals, Common's insider trades

Mangoceuticals, Common Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mangoceuticals, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mangoceuticals, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mangoceuticals, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Isaac Antonios over two weeks ago Insider Trading
		D'alessio Lorraine Pamela over a month ago Acquisition by Dalessio Lorraine Pamela of 100000 shares of Mangoceuticals, Common subject to Rule 16b-3
		Isaac Antonios over two months ago Insider Trading
		Eugene Johnston over three months ago Acquisition by Eugene Johnston of 25000 shares of Mangoceuticals, Common subject to Rule 16b-3
		Jacob Cohen over six months ago Disposition of 8000000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3
		Jacob Cohen over six months ago Disposition of 800000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3
		Hamilton Alex P. over six months ago Disposition of 108426 shares by Hamilton Alex P. of Mangoceuticals Common at 0.32 subject to Rule 16b-3
		Hamilton Alex P. over six months ago Disposition of 16574 shares by Hamilton Alex P. of Mangoceuticals Common at 0.31 subject to Rule 16b-3
		D'alessio Lorraine Pamela over six months ago Acquisition by Dalessio Lorraine Pamela of 100000 shares of Mangoceuticals Common subject to Rule 16b-3
		Jacob Cohen over six months ago Acquisition by Jacob Cohen of 125000 shares of Mangoceuticals Common at 0.32 subject to Rule 16b-3
		Cohen Jacob D over a year ago Mangoceuticals Common exotic insider transaction detected
		Johnston Eugene M over a year ago Acquisition by Johnston Eugene M of 50000 shares of Mangoceuticals Common subject to Rule 16b-3

Mangoceuticals, Common Corporate Filings

8K	25th of March 2025 Report filed with the SEC to announce major events that shareholders should know about	View Verify
10K	20th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance	View Verify
	18th of February 2025 Other Reports	View Verify
	10th of February 2025 Other Reports	View Verify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC